Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.43 |
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | LHCGR | P22888 | 3/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655734 | 1.00 | POLB (0.47) | POLBMAPTNPSR1ATMGRM4 | |
| SCHEMBL5950024 | 0.87 | GRIN2B (0.53) | MAPTNPSR1MEN1KMT2ARAB9A | |
| SCHEMBL4186097 | 0.86 | F10 (0.56) | POLBMAPTATMF10KLKB1 | |
| SCHEMBL20446603 | 0.86 | F10 (0.56) | POLBMAPTATMF10KLKB1 | |
| SCHEMBL75954 | 0.86 | F10 (0.56) | POLBMAPTATMF10KLKB1 | |
| SCHEMBL20446631 | 0.86 | F10 (0.56) | POLBMAPTATMF10KLKB1 | |
| SCHEMBL13890612 | 0.86 | F10 (0.56) | POLBMAPTATMF10KLKB1 | |
| SCHEMBL20446584 | 0.86 | F10 (0.56) | POLBMAPTATMF10KLKB1 | |
| SCHEMBL20446539 | 0.86 | F10 (0.56) | POLBMAPTATMF10KLKB1 | |
| SCHEMBL14040719 | 0.82 | POLB (0.48) | POLBMAPTNPSR1GRM4LHCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710064-B2 | FOR THERAPY OF INFLAMMATORY OR IMMUNE DISEASES | BRISTOL-MYERS SQUIBB CO. | 2004-03-23 | — | — | US | disclosed |
| EP-1339718-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | Bristol-Myers Squibb Company (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
| WO-2002044181-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | HRH4, IL4I1, HRH2 | POLB 4303/4885MAPT 4769/4885NPSR1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.